How HDM1005 affects common drugs
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests how a new medication (HDM1005) affects the way your body absorbs and processes common drugs like metformin, atorvastatin, warfarin, and digoxin. It is for healthy volunteers to understand potential interactions before further testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- Your body mass index (BMI) is between 24 and 35.
- You are in generally good health with no major medical conditions.
- You have no personal or family history of medullary thyroid cancer, pancreatitis, or gallbladder problems.
- You have not taken any prescription or over-the-counter medications (except birth control) in the past 2 weeks.
- You have not donated blood or lost a lot of blood in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental injection called HDM1005 for adults with obesity who do not have diabetes. The goal is to see if it helps with weight loss when combined with diet and exercise.
This study tests how a new injectable medicine called HDM1005 works in your body, with special attention to how your kidneys process it. Researchers want to understand if the medicine is safe for people with kidney problems and healthy people.
This study tests whether a new injectable medication called HDM1005 works as well as tirzepatide (a GLP-1 drug) for weight loss in adults with obesity but no diabetes. Both medications work similarly in the body to help control appetite and weight.
This study tests how a new drug called HDM1002 interacts with common diabetes medications (metformin, empagliflozin) and other drugs like warfarin and valsartan. If you are a generally healthy adult (age 18-45) with a higher BMI, this trial helps ensure the new drug is safe when taken with other medicines.
This study tests how a new drug (HDM1002) interacts with two other common medicines—rifampin and itraconazole—in healthy volunteers. The results will help doctors understand how to safely use the drug with other medications.
This study tests a new injectable medication for weight management in people with overweight or obesity. It investigates how the drug interacts with other medications and checks its safety. Participation requires a 6-month commitment with regular study visits.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.